The aim of this workshop, as with previous HLDA Workshops, is to provide an invaluable and ongoing service to the scientific community.
HLDA9 will study a panel of monoclonal antibodies against B cell-associated molecules. Only monoclonal antibodies against known cloned molecules will be included in the panel. Thus, no unknown antibody blind panels will be carried out. Some antibodies against known CD molecules expressed on B cells will also be included in this panel. MAbs will be provided by both researches and companies.
- Determine the reactivity of the mAbs on normal B cells and B cell malignancies.
- Defining new B cell subsets.
- Determining the expression of the B-cell associated molecules on other hematopoietic and non-hematopoietic cells.
- Identification and expression of intracellular molecules or epitopes of B cell associated molecules.
- Study of phospho-epitopes and other intracellular signaling molecules such as adapter molecules
- Determine the triggered activation/apoptosis induced by therapeutic mAbs, particularly chimeric/ humanised/human mAbs
Sections (updated) The Workshop studies will be coordinated by four chairpersons, each responsible for a section.
For more details on the sections and how you can contribute, click on the links below (opens a new tab).
- Normal B cell and B cell subsets (FACS analysis).
- B-cell malignancies (FACS analysis): Chairman Dr. Valter Gattei (Italy).
- Immunohistochemical analysis of normal and malignant cells.
- Intracellular signaling molecules (FACS analysis and immunohistology).
